Kornimate/medical-research-clean huggingface dataset:
the effect of valacyclovir on the detection of hiv from genital herpes lesions in hiv-infected patients

Conditions: Herpes Simplex; HIV Infections

Summary: the purpose of this study is to see if valacyclovir affects the detection of hiv in genital herpes lesions in hiv-infected patients. valacyclovir is used to treat recurrent genital herpes.

following evaluation for 2 consecutive episodes of genital herpes in this double-blind, crossover study, 30 hiv-1 positive patients are randomized to receive either valacyclovir or placebo. all patients are treated for 10 days.

Eligibility criteria:
inclusion criteria patients must have: * serologically documented hsv-2 and hiv-1 infection. * history of recurrent genital herpes that presents at least 3 recurrences within the 12 months prior to the start of study. * no contraindications to valacyclovir. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: 1. hepatic impairment. 2. impaired renal function (creatinine above 2 mg/dl). 3. malabsorption syndrome or other gastrointestinal dysfunction. 4. any other condition that in the investigator's opinion would interfere with study procedures or successful completion of protocol. patients with the following prior conditions are excluded: history of hypersensitivity to acyclovir or valacyclovir. prior medication: excluded: * participation in any investigational drug trial within 1 month prior to entry on study. * systemic anti-hsv therapy within 7 days prior to start of study drug. 1. probenecid. * suppressive treatment with medication that has anti-hsv activity. required: - stable antiretroviral therapy or no therapy for at least 1 month.

Keywords: hiv-1 antiviral agents herpes genitalis recurrence dna, viral rna, viral valacyclovir herpesvirus 2, human
efficacy of tooth bleaching with 35% and 6% hydrogen peroxide in primary dentition

Conditions: Sensitivity, Tooth

Summary: the aesthetics of dental elements generates great psychological and social impacts, both in the deciduous and permanent dentition. one of the techniques widely used to visually improve the appearance of teeth is bleaching. bleaching can be performed both at home and in a dental office. in office whitening, the technique used consists of applying the whitening gel to the dental surfaces in concentrations ranging from 25% to 50% of hydrogen peroxide. however, recent studies show that low and medium concentration bleaching agents based on hydrogen peroxide have been effective and present a lower risk of sensitivity to the patient. in view of the above, this study aims to carry out a controlled and randomized clinical trial to compare the effectiveness of dental bleaching in deciduous teeth with hydrogen peroxide at concentrations of 35% and 6%. for this, 38 patients aged 03 to 06 years will be selected, allocated in 2 groups (g1 - hydrogen peroxide 35%, n=19 and g2- hydrogen peroxide 6%, n=19). bleaching will be carried out in up to three sessions, with an interval of 7 days between them and the evaluation of color and tooth sensitivity will be carried out 48 hours after each bleaching session. the color assessment will be measured using a digital spectrometer and tooth sensitivity using the pain level scale (wong-baker faces®). descriptive statistical analysis will be carried out, containing the mean and standard deviation in the calculation and normality and homogeneity tests will be carried out, for subsequent adequate statistical analysis. as a result, it is expected that there is no significant difference between the groups in terms of color variation and that the low-concentration bleaching group has the lowest sensitivity index.


Eligibility criteria:
inclusion criteria: * age range from 03 to 06 years old; * vital or non-vital teeth (already endodontically treated) with severe to moderate discoloration; * no active carious lesions; * no lesions in the oral cavity; * no report of previous tooth sensitivity. exclusion criteria: - patients who during anamnesis report allergies to dyes or latex, who withdraw from participating in the study, as well as those who do not attend the callbacks, will be excluded.
prognostic impact of pmi in stable cad undergoing pci

Conditions: Periprocedural Myocardial Injury; Coronary Artery Disease; Percutaneous Coronary Intervention

Summary: this is a single-center, observational, prospective study. this study aims to observe the effect of periprocedural myocardial injury on cardiovascular events in patients undergoing elective percutaneous coronary intervention, and to detect the levels of serum inflammatory factors before and after intervention to predict the occurrence of periprocedural myocardial injury and its association with cardiovascular events.


Eligibility criteria:
inclusion criteria: * underwent elective coronary stenting * patients permit informed consents exclusion criteria: * acute stemi * nyha class iii-iv heart failure * moderate-to-severe valvular disease * missing post-pci troponin results * active infection, respiratory failure * liver dysfunction (liver enzyme \>3xurl or bilirubin \>2xurl), * malignancy and systemic connective tissue disease * unable to get a informed consents
effect of intranasal vasopressin on cooperative behavior in schizophrenia

Conditions: Schizophrenia

Summary: the study investigates the effect of 40iu of intranasal vasopressin on cooperative behavior in patients with schizophrenia


Eligibility criteria:
inclusion criteria: * age 18-45 years * diagnosed as schizophrenia or schizophreniform disorder as per dsm iv tr * at least 7 years of formal education * moca score \>24 exclusion criteria: * diagnoses of siadh, diabetes insipidus * substance dependence in the past 12 months, excluding nicotine dependence * current comorbid axis 1 psychiatric disorder * hypersensitivity or previous allergy to vasopressin * serious medical or neurological illness which may interfere with assessment and administration of vasopressin * hypertension * impaired renal functions based on serum creatinine above 1.5 * electrolyte imbalance * receiving ect or has received ect in the past 8 weeks * clinical history of mental retardation * pregnancy • lactation * risk of harm to self or others * any significant nasal pathology which may hinder the intranasal absorption of the drug * hearing or visual impairment that significantly affects the comprehension and execution of the study
psychological first aid with children in a high risk group - a repeated single case design

Conditions: Post Traumatic Stress Disorder; Adjustment Disorder

Summary: the purpose of this pilot-study is to evaluate a cognitive behavioral method "psychological first aid" used with a group of children (11-16 years) in high risk of developing psychological problems. participants are recruited from a low-threshold program ("the children's house in oslo") where counseling is given to children suspected of being physically or sexually abused, or having witnessed domestic violence. the study includes twelve children and teenagers that receive 2 to 6 sessions of counseling. psychological problems (e.g. anxiety, depression, reactions to trauma) and quality of life will be assessed at pre- post and follow-up (after 3, 6 and 12 months). in addition, some symptoms of will be assessed daily.


Eligibility criteria:
inclusion criteria: * children/adolescents that: * contact "the children's house in oslo" after having experienced potential traumatic event(s). * are assessed as having psychological symptoms related to potential trauma * are between 11 and 16 years old * agree to participate in the study (both the youth and his/her parents(s) * understand and speak norwegian exclusion criteria: - children/adolescents with: * mental retardation * reading skills below 8 year * psychosis * high risk of suicidal behavior is assumed

Keywords: post traumatic stress disorder anxiety symptoms depressive symptoms externalizing behavior reduced quality of life
arq 197 in subjects with metastatic solid tumors

Conditions: Cancer; Tumor

Summary: to determine the safety, tolerability and recommended phase 2 dose (rp2d) of arq 197.

to determine the safety, tolerability and recommended phase 2 dose (rp2d) of arq 197 given orally. this is an open label, dose escalation study of arq 197 administered orally at a starting dose of 10 mg bid (20 mg/day).

Eligibility criteria:
inclusion criteria: * signed written informed consent must be obtained and documented according to ich gcp, the local regulatory requirements, and permission to use private health information in accordance with hippa prior to study-specific screening procedures * a histologically or cytologically confirmed rcc or other c-met expression tumors that is metastatic * patient must have available archival tumor tissue or accessible tumor that is safely amenable to tumor biopsy * ≥ 18 years of age * measurable disease as defined by response evaluation criteria in solid tumors * karnofsky performance status ≥ 70% * male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last arq 197 dose * females of childbearing potential must have a negative serum pregnancy test * aspartate transaminase (ast) and alanine transaminase (alt) ≤ 2.5 × upper limit of normal (uln) or ≤ 5.0 × uln with metastatic liver disease. * hemoglobin (hgb) ≥ 10 g/dl * total bilirubin ≤ 1.5 × uln * creatinine ≤ 1.5 x uln * absolute neutrophil count ≥ 1.5 x 10\^9/l * platelets ≥ 100 x 10\^9/l exclusion criteria: * anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose * surgery within 4 weeks prior to first dose * known brain metastases * pregnant or breastfeeding * significant gastrointestinal disorder(s), in the opinion of the principal investigator, (e.g., crohn's disease, ulcerative colitis, extensive gastric resection) * unable or unwilling to swallow arq 197 capsules twice daily * uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements * bradycardia at baseline or known history of arrhythmia

Keywords: cancer solid tumor metastatic primary tumor
advance supply of emergency contraception compared to routine postpartum care in teens

Conditions: Post Partum

Summary: this is a pilot randomized controlled trial to assess the effects of advanced supply of emergency contraception versus routine care in a teen postpartum population. the goals are to assess feasibility of recruiting and retaining postpartum teens; to obtain estimates of the prevalence of (use of plan b, primary contraceptive continuation, unprotected intercourse exposure, and pregnancy rates), in postpartum teens given advanced supply of plan b; to assess whether or not (lack of use of plan b, contraceptive method non-continuation, and unprotected intercourse exposure), are surrogate markers for risk of unintended pregnancy.


Eligibility criteria:
inclusion criteria: 1. female 2. english speaking 3. aged 14-19 at enrollment 4. immediately postpartum of a live infant 5. planning to parent the baby 6. desiring to delay another pregnancy for at least one year 7. general good health 8. willing and able to follow the study protocol exclusion criteria 1. allergy to levonorgestrel 2. current substance abuse 3. plans for relocation outside of philadelphia

Keywords: teen plan b post partum emergency contraception
capecitabine plus oxaliplatin plus bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this trial will evaluate the efficacy and safety of the capecitabine and oxaliplatine plus bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer.

capecitabine, oxaliplatin and bevacizumab are well known active agents in the treatment of mcrc. the treatment of elderly patients with mcrc is an area of investigation. the role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the colon or rectum * stage iv * existence of two-dimensional measurable disease. the measurable disease should not have been irradiated. * absence or irradiated and stable central nervous system metastatic disease. * life expectancy of more than 3 months. * age ≥ 70 years. * performance status (who) ≤ 2. * adequate bone marrow function (absolute neutrophil count \>1000/mm3, platelet count \>100000/mm3, hemoglobin \>9gr/mm3). * adequate liver (bilirubin \<1.5 times upper limit of normal and sgot/sgpt \<2 times upper limit of normal). * creatinine clearance (cockcroft-gault formula) \>30ml/min. * no other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * presence of a reliable care giver. * informed consent. exclusion criteria: * prior chemotherapy for metastatic disease. * history of thromboembolic disease or myocardial infraction within the last 6 months. * peripheral neuropathy ≥ grade 2. * bowel obstruction or chronic diarrhea. * psychiatric illness or social situation that would preclude study compliance. * other concurrent uncontrolled illness. * other concurrent investigational agents.

Keywords: cancer colorectal cancer elderly chemotherapy capecitabine oxaliplatin bevacizumab
a study to assess the pharmacokinetics and the ability for pediatric participants with type 2 diabetes to swallow mk-0431a xr tablets (mk-0431a-296)

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to assess: 1. the safety and tolerability of two sitagliptin 50 mg/metformin 1000 mg xr tablets in pediatric participants with type 2 diabetes mellitus (t2dm), aged 10 to 17 years 2. the ability of pediatric participants with t2dm, aged 10 to 17 years, to swallow two sitagliptin 50 mg/metformin 1000 mg xr tablets or two matching placebo tablets (excluding marking) 3. the pharmacokinetics of sitagliptin and metformin following the administration of two sitagliptin 50 mg/metformin 1000 mg xr tablets to pediatric participants with t2dm, aged 10 to 17 years.


Eligibility criteria:
inclusion criteria: * female participant of reproductive potential must not be pregnant and agrees to use (and/or have their partner use) two acceptable methods of birth control * t2dm diagnosed by american diabetes association criteria * no clinically significant abnormality on electrocardiogram * no clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes * nonsmoker exclusion criteria: * mental or legal incapacitation * estimated creatinine clearance of 80 ml/min or lower * history of stroke, chronic seizures, or major neurological disorder * history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * history of neoplastic disease * unable to refrain from or anticipates the use of any medication (with the exception of metformin and thyroid hormone) from approximately 2 weeks before the first dose of study drug through the poststudy visit * consumes alcohol or consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages * had surgery, donated or lost 1 unit of blood, or participated in another investigational study within the past 4 weeks * history of multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * currently a regular user (including illicit drugs) or has a history of drug (including alcohol) abuse * lactose intolerant
postoperative chemoradiotherapy with s-1 in gastric cancer

Conditions: Gastric Cancer

Summary: this study was conducted to evaluate the clinical outcomes and toxicities of adjuvant treatment including s-1/cisplatin chemotherapy followed by s-1 based crt.

surgery is the only possible curative treatment of gastric cancer. however, the high recurrence rate makes gastric cancer a disease difficult to cure by surgery alone. despite the benefit of crt on local recurrence, the distant recurrence is the leading pattern of failure. we hypothesized that gastric cancer outcome could be improved using a more effective chemotherapy regimen. this study was conducted to evaluate the clinical outcomes and toxicity of adjuvant treatment including s-1/cisplatin chemotherapy followed by s-1 based crt.

Eligibility criteria:
inclusion criteria: * age \> 18 years * histologically proven gastric adenocarcinoma which is complete resected * ecog performance status of 1 or lower * adequate bone marrow function * absolute neutrophil count \[anc\] ≥1,500µl, and platelets ≥100,000/µl * adequate kidney function (serum creatinine \< 1.5 mg/dl) * adequate liver function (serum total bilirubin \< 2 times the upper normal limit (unl) serum transaminases levels \<2 times unl * no prior chemotherapy exclusion criteria: * other tumor type than adenocarcinoma * evidence of distant metastasis * past or concurrent history of neoplasm except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri * uncontrolled infection * unstable cardiac disease despite treatment, myocardial infarction within months prior to study entry * history of significant neurologic or psychiatric disorders including dementia or seizures * other serious underlying medical conditions which could impair the ability of the patient to participate in the study * symptoms of gastrointestinal obstruction * concomitant drug medication: the following drugs cause drug interaction with s-1.

Keywords: gastric cancer adjuvant chemoradiotherapy s-1 cisplatin
a trial of the efficacy of artesunate and three quinine regimens in the treatment of severe malaria in children at the ebolowa regional hospital - cameroon

Conditions: Malaria

Summary: the purpose of the study is to evaluate and compare the efficacy of parenteral artesunate with three quinine regimens in the treatment of severe malaria in children at the ebolowa regional hospital located in the south region of cameroon


Eligibility criteria:
inclusion criteria: * children presenting with one or more signs of severity of malaria according to the 2013 cameroon national malaria control programme adopted criteria (impaired consciousness, abnormal behaviour, convulsions, prostration, persistent vomiting, jaundice, hyperthermia, acute respiratory distress, clinical acidosis, haemoglobinuria, cardiovascular shock, dehydration, abnormal bleeding, severe anaemia, renal impairment, hypoglycaemia and hyperparasitaemia) * and having an initial positive parasitaemia to plasmodium falciparum * other aetiologies of the presenting symptoms excluded * written consent from parent(s) exclusion criteria: * prior side effects to either artesunate or quinine administration * severely malnourished children * concomitant infection

Keywords: artesunate quinine efficacy malaria children cameroon
bactericidal permeability protein inhibitor and interleukin-1beta levels after non-surgical periodontal treatment

Conditions: Periodontitis

Summary: the aim of this study was to examine the relationship between healing response after non-surgical periodontal treatment and baseline gingival crevicular fluid (gcf) levels of bactericidal/permeability-increasing protein (bpi) and interleukin-1beta (il-1ß).

bactericidal/permeability-increasing proteins (bpi) specific and powerful effect against gram negative bacteria and their lpss is completely observable in biological fluids such as plasma, serum, and whole blood. objective: it is the evaluation of periodontal disease effect of bpi and interleukin-1 beta (il-1 β) levels in gingival fluid before and after non-surgical periodontal treatment (nspt)in patients with periodontal disease. method: thirty systemically healthy and non-smoking individuals with periodontitis were included in the study. before nspt, the clinical parameters of plaque index (pi), gingival index (gi), probing depth (pd), clinical attachment level (cas), bleeding on probing (bop) were measured. the gingival fluid samples were taken using the paper strip method. the same procedures were repeated at 6 weeks and 6 months after non-surgical periodontal treatment. elisa method was used for the analysis of the samples

Eligibility criteria:
inclusion criteria systemically healthy, * stage ii or iii, grade a periodontitis * having at least 20 permanent teeth (excluding third molars and any tooth loss induced by -non-periodontal causes). exclusion criteria: smoking, * use of alcohol; pregnancy or lactation; intake ofantibiotics, steroidal or non-steroidal anti-inflammatory drugs within the last 6 months * having received periodontal treatment within the last 6 months
role of transcranial direct current stimulation in appetite and weight control

Conditions: Weight Loss; Appetite Loss

Summary: to study the effects of transcranial direct current stimulation (tdcs) on weight and appetite.

1. to compare weight loss over one month in active tdcs group with sham tdcs group. the investigator will measure weight of every participants at the beginning of the study and one month after the last session of tdcs 2. to compare change in insulin sensitivity over one month in active tdcs group with sham tdcs group. the investigator will measure fasting insulin and glucose level, and calculate homeostatic model assessment-insulin resistance (homa-ir) 3. to compare change in cognitive performance as a response to food over one month in active tdcs group with sham tdcs group. the investigator will evaluate performance in a computerized task that measures executive functions under the presence of food (working memory, inhibitory control and a combination of both). the investigator will assess changes in accuracy and speed in the task under active tdcs versus sham tdcs. 4. to compare change in post-prandial glucose excursion and average meal counts per day. the investigator will use continuous glucose monitor to record the frequency and amplitude of glucose excursion.

Eligibility criteria:
inclusion criteria: * men and women 18 to 80 years of age * body mass index \> 30 kg/m2 exclusion criteria: * current participation in any other concurrent clinical trials or previous participation within 30 days before the screening visit * pregnancy or premenopausal women who are trying to be pregnant * patients who are incompetent to give consent * obesity due to a known secondary cause (cushing's syndrome, hypothyroidism, etc) or a history of weight loss surgery * have taken any of the following medications within the past 3 months: * phentermine, naltrexone, bupropion, topiratmate, lorcaserin, phendimetrazine, methamphetamine, benzphetamine, diethylpropion * any contraindication to receive transcranial direct current stimulation (tdcs): * personal or family history of seizures, epilepsy or other unexplained loss of consciousness. * current or past history of skin disease or damaged skin on the scalp at the site of stimulation (i.e. eczema, skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.). * prior neurosurgical procedure or radiation. * known diagnosis of brain lesions, such as tumor, stroke or multiple sclerosis * implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, transcutaneous electrical nerve stimulation unit, ventriculo-peritoneal shunt or any metallic implant on the head.

Keywords: tdcs obesity appetite weight loss